Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

BACKGROUND: We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal glycemic patterns by continuous glucose monitoring...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Perkins, Bruce A., Cherney, David Z. I., Soleymanlou, Nima, Lee, Justin A., Partridge, Helen, Tschirhart, Holly, Zinman, Bernard, Mazze, Roger, Fagan, Nora, Kaspers, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., Johansen, Odd Erik
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2015
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4636141/
https://ncbi.nlm.nih.gov/pubmed/26544192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0141085
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items